ICIs are monoclonal antibodies against key regulatory proteins such as programmed death 1 and its ligand (PD1-PDL1) or cytotoxic T-lymphocyte-associated protein 4 (CTLA4), enhancing the immune response against cancer cells. Here, CTLA4 is linked to cancer.